Vertero Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vertero Therapeutics, Inc. - overview
Established
2016
Location
Woburn, MA, US
Primary Industry
Pharmaceuticals
About
Founded in 2016 and headquartered in Woburn, US, Vertero Therapeutics, Inc. , formerly known as Axial Therapeutics, specializes in therapeutics that leverage the gut-brain axis. In October 2025, Vertero Therapeutics, Inc. raised USD 20 million in series D funding from returning investors OneVentures and Seventure, with participation from unspecified investors.
Vertero Therapeutics specializes in the development of innovative small molecule therapeutics targeting the gut microbiome to address diseases and disorders such as autism spectrum disorder (ASD), Parkinson’s disease, liver disease, and oncology. Their lead product candidate, AB-2004, is aimed at treating irritability associated with autism and is currently in a global, randomized, placebo-controlled Phase 2 clinical trial, with results expected in Q1 2024. The company is also advancing its Microbial-Inspired Therapeutics® Platform, which explores the relationship between the microbiome and the nervous system to create transformative therapeutics, primarily targeting healthcare providers in North America and Europe. The company intends to use the January 2025 funding to advance its lead program VT-5006 through Phase 1b trials, prepare for Phase 2, and expand its pipeline focused on neurodegenerative diseases.
Current Investors
Domain Associates, Longwood Fund, Kairos Ventures
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.vertero.com/
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.